Cargando…

PEDT-05 USEFULNESS OF BEVACIZUMAB IN MAINTAINING QOL AT DIPG RELAPSE

INTRODUCTION: Even in the age of molecular diagnosis, diffuse intrinsic pontine glioma (DIPG) is still a dismal disease, and there is no effective treatment. The usefulness of bevacizumab for DIPG relapse is reported. SUBJECTS AND METHODS: The treatment and outcomes of 10 patients with DIPG who were...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomi, Akira, Uchiyama, Taku, Oguma, Hirofumi, Yamaguchi, Takashi, Kawai, Kensuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213212/
http://dx.doi.org/10.1093/noajnl/vdz039.073
_version_ 1783531754671308800
author Gomi, Akira
Uchiyama, Taku
Oguma, Hirofumi
Yamaguchi, Takashi
Kawai, Kensuke
author_facet Gomi, Akira
Uchiyama, Taku
Oguma, Hirofumi
Yamaguchi, Takashi
Kawai, Kensuke
author_sort Gomi, Akira
collection PubMed
description INTRODUCTION: Even in the age of molecular diagnosis, diffuse intrinsic pontine glioma (DIPG) is still a dismal disease, and there is no effective treatment. The usefulness of bevacizumab for DIPG relapse is reported. SUBJECTS AND METHODS: The treatment and outcomes of 10 patients with DIPG who were treated at our institute since 2001 were retrospectively reviewed. All patients were diagnosed with DIPG by MRI imaging and underwent radiation therapy first. Chemotherapy was performed in combination with radiation therapy in 4 cases, and 3 of them did not receive chemotherapy at the time of relapse (Untreated Group). In 7 cases, chemotherapy was performed at the time of relapse with ACNU/vincristine or interferon beta (Other Treatment Group), and 2 cases with bevacizumab (Bv Group). The change in the Karnofsky Performance Status Scale (KPS) from the time of relapse was compared. RESULTS: The average overall survival (OS) for all 10 cases was 10.0 months, 8.1 months in the Untreated Group, 9.5 months in the Bv Group, and 11.4 months in the Other Treatment Group. No prolongation of OS by bevacizumab was observed. However, it was only in the Bv Group that the KPS increased from the time of relapse. Comparison of the KPS at the time of relapse and the KPS after 4 months showed that the Bv Group remained unchanged or increased from 80 to 90, while the Untreated Group decreased by 60–100, and the Other Treatment Group also decreased by 20–50. In the Other Treatment Group, hospitalization was required for treatment, and side effects of bone marrow suppression were observed. However, in the Bv Group, outpatient treatment was possible, there were no side effects, and all could be observed at home. CONCLUSION: From the above results, bevacizumab appears useful for palliative treatment for maintaining quality of life after DIPG relapse.
format Online
Article
Text
id pubmed-7213212
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72132122020-07-07 PEDT-05 USEFULNESS OF BEVACIZUMAB IN MAINTAINING QOL AT DIPG RELAPSE Gomi, Akira Uchiyama, Taku Oguma, Hirofumi Yamaguchi, Takashi Kawai, Kensuke Neurooncol Adv Abstracts INTRODUCTION: Even in the age of molecular diagnosis, diffuse intrinsic pontine glioma (DIPG) is still a dismal disease, and there is no effective treatment. The usefulness of bevacizumab for DIPG relapse is reported. SUBJECTS AND METHODS: The treatment and outcomes of 10 patients with DIPG who were treated at our institute since 2001 were retrospectively reviewed. All patients were diagnosed with DIPG by MRI imaging and underwent radiation therapy first. Chemotherapy was performed in combination with radiation therapy in 4 cases, and 3 of them did not receive chemotherapy at the time of relapse (Untreated Group). In 7 cases, chemotherapy was performed at the time of relapse with ACNU/vincristine or interferon beta (Other Treatment Group), and 2 cases with bevacizumab (Bv Group). The change in the Karnofsky Performance Status Scale (KPS) from the time of relapse was compared. RESULTS: The average overall survival (OS) for all 10 cases was 10.0 months, 8.1 months in the Untreated Group, 9.5 months in the Bv Group, and 11.4 months in the Other Treatment Group. No prolongation of OS by bevacizumab was observed. However, it was only in the Bv Group that the KPS increased from the time of relapse. Comparison of the KPS at the time of relapse and the KPS after 4 months showed that the Bv Group remained unchanged or increased from 80 to 90, while the Untreated Group decreased by 60–100, and the Other Treatment Group also decreased by 20–50. In the Other Treatment Group, hospitalization was required for treatment, and side effects of bone marrow suppression were observed. However, in the Bv Group, outpatient treatment was possible, there were no side effects, and all could be observed at home. CONCLUSION: From the above results, bevacizumab appears useful for palliative treatment for maintaining quality of life after DIPG relapse. Oxford University Press 2019-12-16 /pmc/articles/PMC7213212/ http://dx.doi.org/10.1093/noajnl/vdz039.073 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Gomi, Akira
Uchiyama, Taku
Oguma, Hirofumi
Yamaguchi, Takashi
Kawai, Kensuke
PEDT-05 USEFULNESS OF BEVACIZUMAB IN MAINTAINING QOL AT DIPG RELAPSE
title PEDT-05 USEFULNESS OF BEVACIZUMAB IN MAINTAINING QOL AT DIPG RELAPSE
title_full PEDT-05 USEFULNESS OF BEVACIZUMAB IN MAINTAINING QOL AT DIPG RELAPSE
title_fullStr PEDT-05 USEFULNESS OF BEVACIZUMAB IN MAINTAINING QOL AT DIPG RELAPSE
title_full_unstemmed PEDT-05 USEFULNESS OF BEVACIZUMAB IN MAINTAINING QOL AT DIPG RELAPSE
title_short PEDT-05 USEFULNESS OF BEVACIZUMAB IN MAINTAINING QOL AT DIPG RELAPSE
title_sort pedt-05 usefulness of bevacizumab in maintaining qol at dipg relapse
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213212/
http://dx.doi.org/10.1093/noajnl/vdz039.073
work_keys_str_mv AT gomiakira pedt05usefulnessofbevacizumabinmaintainingqolatdipgrelapse
AT uchiyamataku pedt05usefulnessofbevacizumabinmaintainingqolatdipgrelapse
AT ogumahirofumi pedt05usefulnessofbevacizumabinmaintainingqolatdipgrelapse
AT yamaguchitakashi pedt05usefulnessofbevacizumabinmaintainingqolatdipgrelapse
AT kawaikensuke pedt05usefulnessofbevacizumabinmaintainingqolatdipgrelapse